Celyad Oncology SA (EBR: CYAD)

Celyad Oncology Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	6.23	7	12.45	30.02	17.23	39.34
Cash & Short-Term Investments	6.23	7	12.45	30.02	17.23	39.34
Cash Growth	25.18%	-43.72%	-58.54%	74.18%	-56.19%	-20.91%
Accounts Receivable	0.07	0.38	0.91	0.42	0.4	0.41
Other Receivables	1.01	2.4	0.35	1.92	0.51	2.29
Receivables	1.09	2.78	1.26	2.34	0.91	2.7
Prepaid Expenses	1.31	1.26	0.67	1.69	1.34	0.65
Other Current Assets	0.04	0.08	0.45	0.25	0.22	0.15
Total Current Assets	8.66	11.12	14.83	34.29	19.71	42.84
Property, Plant & Equipment	1.67	1.83	0.31	3.25	4.12	5.06
Goodwill	-	-	-	0.88	0.88	0.88
Other Intangible Assets	0.03	0.05	0.46	34.81	34.75	34.71
Long-Term Accounts Receivable	-	-	-	2.21	2.12	2.43
Long-Term Deferred Charges	0.43	0.34	0.41	0.47	0.54	0.61
Other Long-Term Assets	2.06	2.94	3.72	4.03	3.97	3.31
Total Assets	12.85	16.28	19.72	79.94	66.08	89.84
Accounts Payable	1.06	1.24	4.75	6.61	4.74	6.97
Accrued Expenses	0.35	0.5	1.39	2.13	1.97	2.23
Current Portion of Long-Term Debt	-	-	-	-	0.04	0.19
Current Portion of Leases	0.16	0.16	0.14	0.9	1.08	1.17
Current Unearned Revenue	0.47	0.08	0.89	1.1	1.84	0.67
Other Current Liabilities	0.38	0.96	3.26	3.09	2.18	0.7
Total Current Liabilities	2.42	2.93	10.43	13.83	11.83	11.92
Long-Term Debt	-	-	-	-	-	0.04
Long-Term Leases	0.83	0.9	0.12	1.73	2.53	2.97
Other Long-Term Liabilities	6.33	6.14	4.84	20.69	20.12	28.89
Total Liabilities	9.58	9.98	15.4	36.3	35.09	44.22
Common Stock	8.22	32.95	78.59	78.59	48.51	48.51
Additional Paid-In Capital	-	-	6.32	6.32	43.35	43.35
Retained Earnings	-361.42	-358.37	-349.95	-309	-283.04	-74.42
Comprehensive Income & Other	356.47	331.73	269.36	267.73	222.17	28.18
Shareholders' Equity	3.27	6.3	4.32	43.64	30.99	45.62
Total Liabilities & Equity	12.85	16.28	19.72	79.94	66.08	89.84
Total Debt	0.99	1.06	0.26	2.63	3.64	4.36
Net Cash (Debt)	5.24	5.95	12.19	27.39	13.6	34.98
Net Cash Growth	18.02%	-51.22%	-55.49%	101.43%	-61.13%	-27.28%
Net Cash Per Share	0.15	0.23	0.54	1.76	0.98	2.79
Filing Date Shares Outstanding	41.43	41.43	22.59	22.59	14.21	13.94
Total Common Shares Outstanding	41.43	41.43	22.59	22.59	13.94	13.94
Working Capital	6.25	8.19	4.4	20.47	7.87	30.91
Book Value Per Share	0.08	0.15	0.19	1.93	2.22	3.27
Tangible Book Value	3.24	6.26	3.86	7.95	-4.64	10.03
Tangible Book Value Per Share	0.08	0.15	0.17	0.35	-0.33	0.72
Machinery	-	0.89	1.28	4.01	3.81	4.41
Leasehold Improvements	-	0.64	0.18	4.06	4.03	4.19

Source: S&P Capital IQ. Standard template. Financial Sources.